Suppr超能文献

COVID 后急性后遗症患者的疫苗接种血清学反应。

Serological response to vaccination in post-acute sequelae of COVID.

机构信息

Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

BMC Infect Dis. 2023 Feb 16;23(1):97. doi: 10.1186/s12879-023-08060-y.

Abstract

BACKGROUND

Individuals with post-acute sequelae of COVID (PASC) may have a persistence in immune activation that differentiates them from individuals who have recovered from COVID without clinical sequelae. To investigate how humoral immune activation may vary in this regard, we compared patterns of vaccine-provoked serological response in patients with PASC compared to individuals recovered from prior COVID without PASC.

METHODS

We prospectively studied 245 adults clinically diagnosed with PASC and 86 adults successfully recovered from prior COVID. All participants had measures of humoral immunity to SARS-CoV-2 assayed before or after receiving their first-ever administration of COVID vaccination (either single-dose or two-dose regimen), including anti-spike (IgG-S and IgM-S) and anti-nucleocapsid (IgG-N) antibodies as well as IgG-S angiotensin-converting enzyme 2 (ACE2) binding levels. We used unadjusted and multivariable-adjusted regression analyses to examine the association of PASC compared to COVID-recovered status with post-vaccination measures of humoral immunity.

RESULTS

Individuals with PASC mounted consistently higher post-vaccination IgG-S antibody levels when compared to COVID-recovered (median log IgG-S 3.98 versus 3.74, P < 0.001), with similar results seen for ACE2 binding levels (median 99.1 versus 98.2, P = 0.044). The post-vaccination IgM-S response in PASC was attenuated but persistently unchanged over time (P = 0.33), compared to in COVID recovery wherein the IgM-S response expectedly decreased over time (P = 0.002). Findings remained consistent when accounting for demographic and clinical variables including indices of index infection severity and comorbidity burden.

CONCLUSION

We found evidence of aberrant immune response distinguishing PASC from recovered COVID. This aberrancy is marked by excess IgG-S activation and ACE2 binding along with findings consistent with a delayed or dysfunctional immunoglobulin class switching, all of which is unmasked by vaccine provocation. These results suggest that measures of aberrant immune response may offer promise as tools for diagnosing and distinguishing PASC from non-PASC phenotypes, in addition to serving as potential targets for intervention.

摘要

背景

患有 COVID 后急性后遗症(PASC)的个体可能存在持续的免疫激活,这使他们与没有临床后遗症从 COVID 中康复的个体不同。为了研究体液免疫激活在这方面可能存在的差异,我们比较了 PASC 患者与没有 PASC 从先前 COVID 中康复的个体的疫苗引发的血清学反应模式。

方法

我们前瞻性研究了 245 名临床诊断为 PASC 的成年人和 86 名成功从先前 COVID 中康复的成年人。所有参与者在接受首次 COVID 疫苗接种(单剂或两剂方案)之前或之后均进行了针对 SARS-CoV-2 的体液免疫测量,包括针对刺突蛋白(IgG-S 和 IgM-S)和核衣壳蛋白(IgG-N)的抗体以及 IgG-S 血管紧张素转换酶 2(ACE2)结合水平。我们使用未经调整和多变量调整的回归分析来检查与 COVID 恢复状态相比,PASC 与疫苗接种后体液免疫的测量值之间的关联。

结果

与 COVID 恢复相比,患有 PASC 的个体在接种疫苗后始终表现出更高的 IgG-S 抗体水平(中位数 log IgG-S 为 3.98 对 3.74,P <0.001),ACE2 结合水平也存在类似的结果(中位数为 99.1 对 98.2,P =0.044)。与 COVID 恢复相比,PASC 中的疫苗接种后 IgM-S 反应减弱但随时间推移持续不变(P =0.33),而 COVID 恢复中预期的 IgM-S 反应随时间推移而降低(P =0.002)。在考虑人口统计学和临床变量(包括指数感染严重程度和合并症负担指数)时,结果仍然一致。

结论

我们发现有证据表明免疫反应异常可以区分 PASC 和从 COVID 中恢复的患者。这种异常表现为 IgG-S 的过度激活和 ACE2 结合,同时还存在与免疫球蛋白类别转换延迟或功能障碍一致的发现,所有这些都是由疫苗激发引起的。这些结果表明,异常免疫反应的测量值可能有希望作为诊断和区分 PASC 与非 PASC 表型的工具,同时也可能成为干预的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e87b/9936700/b74b012b8f54/12879_2023_8060_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验